InMed Pharmaceuticals to Attend and Exhibit at EB2020 World Congress

January 16, 2020

Read More »

InMed Announces Election of Directors

January 10, 2020

Read More »

InMed Pharmaceuticals to Present at the Biotech Showcase Conference

January 8, 2020

Read More »

InMed Receives Clinical Trial Application Approval for INM-755, a Rare Cannabinoid Formulation Under Development for the Treatment of Epidermolysis Bullosa

December 9, 2019

Read More »

InMed Pharmaceuticals to Present at the Cowen Conference

November 11, 2019

Read More »

InMed Pharmaceuticals Reports First Quarter Fiscal 2020 Financial Results and Provides R&D and Business Update

November 8, 2019

Read More »

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

November 5, 2019

Read More »

InMed Pharmaceuticals to Report First Quarter Fiscal 2020 Financial Results and Business Update on November 8, 2019

November 4, 2019

Read More »

InMed Pharmaceuticals to Present at the BIO Investor Forum

October 18, 2019

Read More »

InMed Pharmaceuticals to Present at the Regulatory Affairs Professionals Society’s annual conference

September 23, 2019

Read More »

InMed Pharmaceuticals Reports Fourth Quarter and Full Year Fiscal 2019 Financial Results and Provides R&D and Business Update

September 19, 2019

Read More »

InMed Pharmaceuticals to Report Fourth Quarter, and Full Year Fiscal 2019 Financial Results and Business Update on September 19, 2019

September 12, 2019

Read More »

InMed Pharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

September 3, 2019

Read More »

InMed Pharmaceuticals to Attend the 2nd Annual International Cannabinoid-Derived Pharmaceuticals Summit

August 29, 2019

Read More »

InMed Pharmaceuticals Appoints Bruce S. Colwill, CPA, CA as Chief Financial Officer and Announces other Leadership Changes

August 2, 2019

Read More »

InMed Pharmaceuticals Appoints Catherine Sazdanoff to Board of Directors

July 2, 2019

Read More »

InMed Pharmaceuticals Reports Third Quarter Fiscal 2019 Financial Results and Provides R&D and Business Update

May 15, 2019

Read More »

InMed Pharmaceuticals to Report Third Quarter Fiscal 2019 Financial Results and Business Update on May 15, 2019

May 8, 2019

Read More »

InMed Continues to Strengthen IP Portfolio for its Biosynthesis Platform Technology

March 18, 2019

Read More »

InMed Pharmaceuticals Announces Transition to a Single Cannabinoid Investigational Drug Candidate – INM-755 – for its Epidermolysis Bullosa Program

March 13, 2019

Read More »